Top Page
MAIA Biotechnology, Inc.
(MAIA)
MAIA Biotechnology, Inc. (MAIA) vs. SPDR S&P 500 ETF (SPY)
MAIA Biotechnology, Inc. Business Overview & Revenue Model
MAIA Biotechnology, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -10.13M | -23.25M | -19.77M | -15.76M | -11.75M | 0.00 |
| Net Income | -22.34M | -23.25M | -19.77M | -15.77M | -12.50M | -6.64M |
Balance Sheet | ||||||
| Total Assets | 11.78M | 10.16M | 7.57M | 12.02M | 11.33M | 746.50K |
| Cash, Cash Equivalents and Short-Term Investments | 10.89M | 9.60M | 7.15M | 10.95M | 10.57M | 663.46K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 463.75K |
| Total Liabilities | 11.74M | 6.52M | 7.09M | 3.51M | 2.15M | 2.36M |
| Stockholders Equity | 41.67K | 3.63M | 477.51K | 8.51M | 9.18M | -3.34M |
Cash Flow | ||||||
| Free Cash Flow | -15.73M | -15.70M | -13.07M | -12.10M | -4.12M | -1.84M |
| Operating Cash Flow | -15.73M | -15.70M | -13.07M | -12.10M | -4.12M | -1.84M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 17.95M | 18.18M | 9.27M | 12.48M | 14.03M | 798.05K |
MAIA Biotechnology, Inc. Technical Analysis
MAIA Biotechnology, Inc. Risk Analysis
MAIA Biotechnology, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $33.90M | -0.98 | -908.28% | ― | 588.40% | 61.76% | |
47 Neutral | $59.17M | -1.50 | -98.81% | ― | ― | ― | |
45 Neutral | $37.56M | -1.84 | -61.92% | ― | -100.00% | 55.10% | |
44 Neutral | $61.10M | -2.22 | -2691.06% | ― | ― | 44.50% | |
43 Neutral | $14.42M | -0.99 | -680.47% | ― | ― | ― | |
42 Neutral | $43.22M | -0.52 | -115.64% | ― | ― | 46.20% |
MAIA Biotechnology, Inc. Corporate Events
On December 16, 2025, MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement with accredited investors and directors for a private placement of common stock and warrants worth approximately $2.25 million. The director participation aligns leadership interests with shareholders, and the funds will support Phase II clinical trials of the THIO-101 program as well as general working capital. The transaction is expected to close on December 18, 2025, pending standard closing conditions.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On December 11, 2025, MAIA Biotechnology, Inc. announced significant insider buying by its leadership, including CEO Dr. Vlad Vitoc, who acquired 182,445 shares in late November 2025. This insider activity, alongside encouraging clinical results from their telomere-targeting cancer therapy, ateganosine, signals strong confidence in the company’s strategy and potential for long-term value creation. The company also announced the dosing of the first patient in the THIO-104 Phase 3 pivotal trial, marking a critical step in evaluating ateganosine as a third-line treatment for advanced non-small cell lung cancer. These developments are seen as pivotal for MAIA’s positioning in the oncology market and its potential impact on stakeholders.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On December 10, 2025, MAIA Biotechnology announced a significant advancement in the treatment of advanced non-small cell lung cancer (NSCLC) with their telomere-targeting agent, ateganosine. This new therapeutic class aims to address the unmet medical needs of patients who do not respond to current therapies like checkpoint inhibitors or chemotherapy. The company has received Fast Track Designation from the U.S. FDA and is initiating a Phase 3 trial, positioning itself strategically in the oncology market. The potential success of ateganosine could redefine treatment paradigms for NSCLC and extend its impact across other cancer types, supported by FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On November 21, 2025, MAIA Biotechnology announced the ongoing progress of its ateganosine clinical program at the SITC 2025 conference. The company highlighted the enrollment of 12 patients in the Phase 2 THIO-101 trial and the commencement of patient screening in the Phase 3 THIO-104 trial for NSCLC. The FDA has granted Fast Track designation for ateganosine, which has shown promising results in extending overall survival in patients resistant to current treatments. The trials are expected to advance the development of ateganosine as a novel therapy for NSCLC, potentially leading to early commercial approval and offering new hope for patients with significant unmet medical needs.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On November 20, 2025, MAIA Biotechnology announced that its CEO, Vlad Vitoc, presented the efficacy of their telomere-targeting agent, ateganosine, at the Smart Diaspora 2025 conference in Romania. The company has begun enrolling patients in Romania for the Phase 2 THIO-101 Part C study, which evaluates ateganosine as a treatment for advanced non-small cell lung cancer. This expansion aims to accelerate patient access to the therapy and strengthen MAIA’s strategy for accelerated approval in the U.S. The study has shown promising results, with a 38% response rate in third-line NSCLC patients, compared to the current treatment’s response rate of up to 6%.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
MAIA Biotechnology, Inc. announced the presentation of two posters at the Society for Immunotherapy of Cancer conference in November 2025. The posters detail ongoing Phase 2 and Phase 3 studies of Ateganosine (THIO) in combination with immune checkpoint inhibitors for treating advanced NSCLC resistant to standard therapies, highlighting the company’s commitment to advancing cancer treatment options.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On October 27, 2025, MAIA Biotechnology announced its participation in the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, where they presented a trial in progress poster for their THIO-101 Phase 2 clinical trial. The company has enrolled five patients from Taiwan and Turkey in the expansion phase of this trial, which aims to evaluate the anti-tumor activity of ateganosine in combination with immune checkpoint inhibitors for advanced NSCLC patients. This development could offer a promising treatment option for the large and underserved NSCLC patient population, particularly in regions with high lung cancer prevalence due to factors like smoking and air pollution.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On October 23, 2025, MAIA Biotechnology announced the presentation of two e-posters at the European Society for Medical Oncology Congress 2025 in Berlin, detailing ongoing Phase 2 and Phase 3 clinical trials of ateganosine in non-small cell lung cancer (NSCLC). A notable highlight was the 30-month survival of a patient in the Phase 2 trial, which underscores the potential efficacy of ateganosine in treating high-risk cancers with limited options. This development could significantly impact MAIA’s position in the oncology market, offering hope for patients resistant to existing therapies.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On October 13, 2025, MAIA Biotechnology, Inc. announced a Securities Purchase Agreement with accredited investors for a private placement of 603,769 shares of common stock and warrants, raising approximately $736,600. The proceeds will be used to fund the initial costs of Step 1 of Part C of the Phase II trial THIO-101 and for working capital, with the private placement expected to close on October 15, 2025.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
On October 7, 2025, MAIA Biotechnology, Inc. announced a new digital asset treasury strategy, authorizing up to 90% of its liquid assets to be held in cryptocurrencies such as Bitcoin, Ethereum, and USD Coin. This move aims to diversify MAIA’s investment portfolio and enhance value creation for shareholders while maintaining adequate working capital for operations. The company plans to establish a Digital Assets Advisory Board to support this strategy, reflecting a strategic shift towards leveraging the rapidly evolving blockchain space.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.